AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 301 min read$ABEO

Vasanthavada Madhav sold $25K of ABEO

Vasanthavada Madhav (Chief Commercial Officer) sold 4,902 shares of ABEONA THERAPEUTICS INC. (ABEO) at $5.16 on 2026-09-29.

Original reporting
SEC EDGAR · Vasanthavada Madhav
Published Sep 30, 2026, 1:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 2:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABEO
Bearish
medium confidence
Mentioned
$ABEO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEOBearishLow
01

Why it matters

A modest insider sell by a senior executive may cause slight short-term price pressure.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

No 10b5-1 plan; could indicate lack of confidence, but size is small.

Relevance 3/10Novelty 3/10Timing: after-hours filing

Background

Form 4 disclosures provide primary source data on insider transactions.

Company-level read

Ticker impact

$ABEOBearishMedium confidence
Context

Chief Commercial Officer sold 4,902 shares for $25,272.75 in a Form 4 filing.

Expected impact

likely modest downward pressure as market prices in the insider sell

Evidence & confidence

The sale is small relative to holdings and typical for 10b5-1 plans, but still a sell by an executive.

Market effects

Sector

Minimal impact on biotech sector; insider sales are common.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be routine liquidity need, not a negative signal.

Key entities

  • Company
    Abeona Therapeutics Inc.

    Biotech firm listed on NASDAQ (ABEO).

  • Individual
    Vasanthavada Madhav

    Chief Commercial Officer of Abeona.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABEO insider trading history →

Related articles

SEP 26
$ABEOMed

Abeona, NexGen, Nano Nuclear, SanDisk, Tempus Trending

Analysts initiated coverage on five stocks: Abeona (ABEO) with a $17 target, NexGen (NXE) at $14, Nano Nuclear (NNE) at $33, SanDisk (SNDK) at $2,400, and Tempus (TEM) at $75. Abeona's ZEVASKYN gene therapy, NexGen's uranium project, Nano Nuclear's KRONOS reactor, SanDisk's AI infrastructure, and Tempus's diagnostics business are key focuses.

tipranks.com3 min
SEP 18
$ABEOHighAI 9/10

Abeona Therapeutics Inc.: Abeona Therapeutics Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics (ABEO) congratulated Ultragenyx (RARE) on FDA approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). Abeona initially developed the therapy and licensed it to Ultragenyx in 2022, making it eligible for milestone payments and royalties. FAYUVI addresses a rare, progressive neurodegenerative disease with high unmet medical need.

finanznachrichten.de2 min
AUG 13
$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

rttnews.com4 min